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Relevance of the bioregulatory approach
At the present moment, medicine considers the osteo-
arthrosis/osteoarthritis (OA) as a degenerative-dystrophic 
process in the articular cartilage, at which there are noted 
pathologically altered areas of the cartilage and adjacent 
bone, in which it is disturbed the equilibrium between the 
degradation and synthesis processes that leads to destruc-
tion of the cartilage and a characteristic rearrangement of 
the subchondral bone plate [3, 15].
At the therapy of the OA are most widely used in the 
world chondroprotective compounds, NSAIDs, CS, less of-
ten – antioxidants, vitamins, minerals, osteotropic medical 
preparations (MP) and improving intraosseous and regional 
blood circulation, etc. [2,15]. However, at a long-term use, 
a number of MP cause various side effects – gastropathies, 
colitis, cardiomyopathy, influence on arterial tension indices, 
decrease of the filtration function of kidneys, toxic hepatitis, 
secondary osteoporosis, etc. [2,3,15]. The same happened 
also with the COX-2 inhibitors (selective NSAIDs). It turned 
out that in case of the decrease of analgesic effect, patients 
increase independently the single and, correspondingly, the 
daily therapeutic dose that leads to a sharp increase of side 
effects, including with a lethal outcome. Foreign experts note 
that this process has an uncontrollable character. The treat-
ment of the OA is complicated also by age restrictions and 
inability of the use of traditional MP in this or that concomi-
tant pathology. Development of the majority of undesirable 
side effects, the presence of limitations and contraindications 
is related to pharmacological paradigm of the accumulation 
of a certain concentration of the active substance in order to 
provide an impact on a certain “target” (for example, block-
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Abstract
Background: In the article it is considered the essence and possibilities of the bioregulatory approach in the therapy of osteoarthrosis/osteoarthritis 
(OA) that is realized with the help of the use of complex bioregulatory medications (CBM) of the German company Biologische Heilmittel Heel GmbH. 
It is described in detail the composition and characteristics of the CBM Zeel T – the chondroprotective compound with a bioregulatory action. Zeel T 
is registered in the Republic of Moldova as a solution for injections, sublingual tablets and cream. Zeel T contributes to the restoration of the disturbed 
metabolic and reparative processes in the articular cartilage. There are considered important distinguishable moments of the mechanism of Zeel T action 
from the traditional chondroprotective compounds and its advantages. It should be noted that Zeel T has more than 40 years research history and it is 
widely used in more than 30 countries. Every year almost one million patients worldwide are treated with Zeel T. In the article it is presented the overview 
of clinical studies on the use of Zeel T at OA that demonstrate that Zeel T has comparable clinical efficacy with various traditional medicinal products (MP).
Conclusions: It has also a good tolerability, does not cause characteristic for NSAIDs and corticosteroids (CS) side effects, and therefore can be used 
for a long time. The medicine is well combined with other medicinal products that increases the effectiveness and reduces the duration of the treatment 
course of OA.
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ing of COX or certain receptors, occurrence of the excess of 
the administered substrate at the use of average therapeutic 
dose, without establishment of individual dose). The devel-
opment of habituation and decrease of the effectiveness of 
MP is associated also with the paradigm of the use of large 
doses of active substance, the task of which is by the “force” 
of high concentration to keep control over the symptoms in 
the needed parameters.
In connection with this, there remains an urgent need 
to optimize the treatment regimens of the OA with the help 
of MP that have other mechanisms of action and allow en-
suring simultaneously high efficacy and safety of treatment. 
Also, taking into consideration a high risk of the appearance 
of side effects and poor tolerability of MP at a long-term ad-
mission, it is also important the object of the reduction of the 
duration of their use [15].
As the world clinical experience shows, the above-men-
tioned tasks are solved successfully by the inclusion in the 
OA therapy regimens of complex bioregulatory medica-
tions (CBM) that were previously called in the literature 
as antihomotoxic medications (AHTM). The bioregulatory 
effect is exerted by ultra-small doses (USD) of the active 
substances of the CBM that are obtained with the help of 
homeopathic technology. This “pharmacology of ultra-small 
doses”, thanks to a different mechanism of action, introduces 
fundamentally new possibilities in the treatment regimens 
of the “pharmacology of large doses” (traditional MP), that 
at a correct and timely administration, makes it possible to 
improve significantly the effectiveness of standard therapy 
regimens. At the same time, the acceleration and quality of 
recovery is caused by the activation of the processes of self-
healing/reparation, due to the launch of USD recovery of 
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self-regulation processes in the body [4-6,9,15]. Also, USD 
are not metabolized in the body and are not energy-consum-
ing for it, and therefore do not have an additional pharmaco-
logical load on the body.
Characteristics of Zeel T
For treatment of the OA, in the capacity of basic CBM it 
is used the Zeel T. In the Republic of Moldova, the medica-
tion is presented in three dosage forms: injection solution, 
sublingual tablets and cream (during the last re-registration 
by the manufacturer there was specified the basis of the dos-
age form “ointment” and changed to “cream”). What is the 
difference between Zeel T and traditional chondroprotective 
compounds? It does not introduce various components of the 
connective tissue into the body but has a chondroprotective 
effect due to bioregulatory effect on the metabolism of chon-
drocytes and fibroblasts. It restores the efficiency of energetic 
and metabolic processes in them that improves the synthesis 
of the missing components of the articular cartilage.
At the same time Zeel T has an anti-inflammatory and 
analgesic effect. The inclusion of the given CBM in the stan-
dard therapy regimens improves the efficiency of the assimi-
lation of connective tissue components that come with clas-
sical chondroprotective compounds [7,8,9,15].
Clinical efficiency of Zeel T was confirmed by numer-
ous clinical studies: observational, cohort, prospective, mul-
ticentre, randomized, placebo-controlled, double-blind, in 
vitro [15].
The dosage and mode of administration of Zeel T are 
presented in the table 1.
Clinical researches
Italian scholars conducted a clinical study “Research 
of therapeutic efficiency and tolerability of antihomotoxic 
medication “Zeel T”, in which with the help of the method 
of diffractometric and polarising-microscopic investiga-
tion, before and after the course of intra-articular injections 
Zeel T, there were studied the samples of patients’ cartilages. 
After therapy, the structure of the cartilaginous tissue was 
significantly improved and no cases of poor tolerance were 
recorded. This confirms the pronounced chondroprotective 
effect of Zeel T [10].
The use of Zeel T in the form of ointment at degenera-
tive joint diseases was described by the German specialists 
in the study “Therapy of Degenerative Joint Diseases by the 
medication Zeel T – the results of a multicentre investigation 
of 498 patients”. At the evaluation of the tolerability of the 
ointment Zeel T in 95% of the cases there were registered the 
results “very good” and “good”. At the same time in 75.1% of 
cases, the effectiveness of therapy with the help of the given 
CBM was assessed as “good” and “very good”, in 17.5% – 
“satisfactory”, i.e. therapeutic effect was observed in 92,6% 
of cases. Whereby the highest score received the therapy of 
monoarthrosis with the help of the ointment Zeel T – 76.1% 
of good and excellent assessments [7,15].
The efficiency of the medication Zeel T (tablets) in com-
parison with diclofenac was studied in 121 patients with 
gonarthrosis within the framework of a double-blind ran-
domized study conducted by the German doctors. At the 
end of the 10-week course of therapy, there was noted a vera-
cious clinical improvement of the mobility and functionality 
of the affected knee joint in both groups of patients. While 
the effect of the investigated CBM appeared to be equivalent 
to the efficiency of diclofenac, in case of the use of the latter 
there were noted repeatedly side effects (primarily – on the 
part of gastrointestinal tract). The fact that was not observed 
at the use of the medication Zeel T. It was concluded that 
the therapy of light and medium forms of gonarthrosis with 
the help of the medication Zeel T leads to a significant im-
provement of the mobility, reduction of pain sensations that 
improves the quality of life of patients [12].
The data of comparative study showed that to its effec-
tiveness the periarticular injections Zeel T are comparable 
with intraarticular injections. The results of the therapy by 
periarticular injections were evaluated as good, the tolerance 
of the medication was assessed as excellent. It should be not-
ed that at the execution of periarticular injections there is no 
risk of the contamination of joint. Thus, the injections Zeel 
T should be administered subcutaneously or intradermally, 
as close as possible to the affected joint [13].
By Lviv specialists in the work “Osteoarthritis of knee 
joints in patients with somatic pathology: experience of com-
plex conservative treatment with the inclusion of AHTM” 
there was studied the possibility of the use of CBM (Zeel 
T and other CBM) in the therapy of the patients with the 
OA of knee joints with severe progressive chronic somatic 
diseases that limited the use of pharmacological allopathic 
Table 1
Use of the dosage forms of CBM Zeel T depending on the period of OA
Dosage form Acute period, exacerbation Continuation of treatment course
Solution for injections*
(ampoules of 2,0 ml each)
1 amp. every other day №5 1 amp. 2 times/week - №5-10
Tablets
(50 tabl. in container)
1 tab. sublingually every 30 minutes – 1 hour (15 minutes before 
meals or 1 hour after), up to 12 times per day, the first 2-3 days
1 tabl. 3 times/day
Cream
(50 g in tube)
4-5 cm of cream to apply to the skin in the area of the affected 
joint and to rub in easily: up to 4 times/day in the first 2-3 days
To rub in 2-3 times/day (administration can be 
combined with phonophoresis, amplipulse)
*solution for injections is injected: intramuscularly, intraarticularly, subcutaneously and intradermally paraarticularly (circumarticularly) and at 
spondyloarthrosis – paravertebrally.
REvIEw ARTIClES The Moldovan Medical Journal, June 2018, Vol. 61, No 2
MP. The results indicate high efficiency, good tolerability and 
sufficient level of safety of the therapy by Zeel T and other 
CBM in patients with gonarthrosis of radiologic stages II-
III. Also, the authors noted that the treatment with the help 
of CBM contributes to positive dynamics of clinical signs of 
acute inflammatory articular syndrome, reducing the pain 
and movement limitation, improving the functional capacity 
of joints and improving the quality of life of patients [14].
In the research thesis “Influence of glucocorticoids and 
antihomotoxic medications on articular cartilage at its me-
chanical damage in athletes” it was shown that intra-articu-
lar injection of the medication Zeel T in the early stages of 
the damage of articular cartilage of the knee joint causes the 
suppression of the development of degenerative-dystrophic 
process and positively influences the formation of chondroid 
tissue in the defect of articular cartilage [17].
In the research thesis “Treatment of gonarthrosis by 
homeopathic medication Zeel T in the conditions of poly-
clinic” there are presented comparative data of two schemes 
of the 4-week therapy of gonarthrosis in 80 patients. The 1st 
scheme: 40 people received NSAIDs, vascular medications, 
physiotherapy. The 2nd scheme: to 40 patients was addition-
ally prescribed the medication Zeel T (tablets). The control 
of the results of the investigation was carried out according 
to clinical and ultrasound study of knee joints for 1 year. It 
is objectively proved that combination of allopathic therapy 
with the medication Zeel T gives a more pronounced and 
persistent therapeutic effect, manifested by the reduction of 
pain and improvement of the function of knee joints. The 
combination of traditional treatment with Zeel T is recom-
mended in case of periarthritis, tendinitis, mildly/moderate-
ly pronounced forms of synovitis and at their combination. 
The given thesis was awarded the International Prize of G.G. 
Reckeweg for 2001 [18, 19].
German scientists conducted a comparative study on 
the use of the medication Zeel T and hyaluronic acid for the 
therapy of gonarthrosis [21]. Both medications demonstrat-
ed similar therapeutic efficiency with a good analgesia, while 
side effects at the treatment with the help of Zeel T were 2 
times less frequent (5,5%) than at the use of hyaluronic acid 
(11%). Also, the total cost of treatment course with the help of 
Zeel T was 2 times lower. In another study in Germany in the 
course of multicentre randomized blind controlled investiga-
tion there was carried out the comparison of the efficiency 
and tolerability of the medications Zeel T and hyaluronic acid 
in the treatment of the OA of knee joint. Within 5 weeks, pa-
tients received 10 injections of Zeel T or 5-of hyaluronic acid 
(2 groups of 57 patients in each). The therapeutic efficiency 
of Zeel T was recognized as equivalent to hyaluronic acid, not 
only in patients suffering of medium intensity pain, but also 
in patients with severe pain. At the same time, the use of Zeel 
T twice as less led to undesirable effects. The results of the 
given investigation confirm the favourable experience of the 
use of Zeel T, collected for many years [20].
At the department of traumatology and orthopaedics of 
the Lviv National Medical University there were elaborated 
methodical recommendations of the Ministry of Health 
of Ukraine on the application of CBM in the pathology of 
the joints and vertebral column: “Pathogenetically directed 
medicinal therapy of destructive-dystrophic diseases of the 
vertebral column and joints”. It is noted that Zeel T contribu- 
tes to the transfer of arthrogenic disease during the period 
of persistent remission, and the inclusion of CBM in the 
therapy schemes contributes to significant improvement of 
the results of treatment, makes it possible to reduce the dos-
age of allopathic MP, and in some cases, to cancel them [11].
Table 2
Combination of Zeel T dosage forms and dosage at different stages of OA
Stage of 
ОА






To start with the initiation mode: 1 tab. 
every 30 minutes – 1 hour, up to 12 
times a day, the first 2-3 days
Further to take 1 tab. 3 times/day, 
5-7 weeks - During 5-7 weeks
- 2 times/year 





To start with the initiation mode: 1 
amp. every other day, №5
–
- During 7-9 weeks
- 2-3 times/yearTablets – 1 tab. 3 times/day During 5-7 weeks




To start with the initiation mode: 1 
amp. every other day, №5
2 times/week №5-10.
Total for course: №10-15
- During 10-12 weeks
- 2-3 times/yearTablets –






To start with the initiation mode: 1 
amp. every other day, №5
2 times/week №10-15
Total for course: №15-20
- During ≈ 3 months 
- 3 times/yearTablets –
After the course of injections: 1 tab. 3 
times/day, 5 weeks
Cream Up to 4 times/day in the first 2-3 days 2-3 times/day
*solution for injections is injected: intramuscularly, intraarticularly, subcutaneously and intradermally – paraarticularly (circumarticularly) and in case 
of spondyloarthrosis – paravertebrally.
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Practical recommendations
A faster and more pronounced clinical effect in the treat-
ment of the OA is achieved by the combination of systemic 
and local dosage forms of the medication Zeel T: injections 
with cream and tablets with cream (recommendations in 
the table 2) [2,8,11].
Conclusions
On the basis of the properties of Zeel T and clinical stud-
ies [1-3, 7-15, 19-21], the following conclusions can be made:
1. Zeel T is a complex chondroprotective compound, 
which, unlike traditional chondroprotective compounds, 
has a different bioregulatory mechanism of action.
2. Zeel T has similar therapeutic efficiency with tradi-
tional MP.
3. Zeel T has a good tolerability, without causing herewith 
the side effects characteristic for NSAIDs and other MP.
4. The presence of three dosage forms of the medication 
Zeel T allows to choose for each patient the most optimal or 
to use the combination of them.
5. Zeel T can be used as a monotherapy or in combina-
tion with other MP that contributes to the reduction of the 
duration of treatment course and increase of its effectiveness.
References
1. Motsar’ SI, Ignat’ev EO. Opyt primeneniia antigomotoksicheskikh pre-
paratov Traumeel S, Zeel T, Discus compositum v terapii deformiruiush-
chikh artrozov, spondiloartrozov i osteokhondroza pozvonochnika 
[Experience of the use of antihomotoxic medications Traumeel S, Zeel 
T, Discus compositum in the therapy of deforming arthrosis, spondylo-
arthrosis and osteochondrosis of the vertebral column]. Biologicheskaia 
Terapiia. 2000(2):34-42. Russian.
2. Aver’ianov EV. Bioreguliatsionnyi podkhod v terapii degenerativno-dis-
troficheskikh zabolevanii oporno-dvigatel’nogo apparata [Bioregulatory 
approach in the therapy of degenerative-dystrophic diseases of the mus-
culoskeletal system]. Biologicheskaia Terapiia. 2012;(3-4):8-13. Russian.
3. Fishchenko VO, Ladon’ko IuL, Al’-Shalabi Alla: Dosvіd vikoristannya 
preparatіv Traumeel S ta Zeel T v lіkuvannі gonartrozu [Experience 
of the use of the medications Traumeel S and Zeel T in the treatment 
of gonoarthrosis]. Vіsnik Vіnnits’kogo Derzhavnogo Medichnogo 
Unіversitetu (Vinnytsia). 2001;(1):209-11. Ukrainian.
4. Klimenko VG. Osnovnye polozheniia patogeneticheskogo bioreguliatsi-
onnogo podkhoda v obshchei terapevticheskoi praktike [Basic provisions 
of pathogenetic bioregulatory approach in general therapeutic practice]. 
Biologicheskaia Terapiia. 2013;(1):8-11. Russian.
5. Khartmut Kh. Znachenie antigomotoksicheskoi terapii v reguliatornoi 
meditsine [Significance of antihomotoxic therapy in regulatory medi-
cine]. Biologicheskaia Meditsina. 2004;(2):4-9. Russian. 
6. Van Brandt B, Khayne Khartmut. Reguliatornaia blokada: opredelenie, 
znachenie i terapiia [Regulatory blockade: definition, significance and 
therapy]. Biologicheskaia Meditsina. 2006;(2):4-5. Russian. 
7. Vodik RE, Steininger K, Zenner S. Terapiia degenerativnykh zabolevanii 
sustavov preparatom Zeel T – rezul’taty mul’titsentricheskogo obsledo-
vaniia 498 patsientov [Therapy of degenerative diseases of the joints 
with the help of medication Zeel T – results of multicentric examination 
of 498 patients]. Biologicheskaia Meditsina. 1995;(1):27-34. Russian.  
8. Vol’dans’ka-Okons’ka M, Rykala-Koval’s’ka A. Srav-nitel’naia otsenka 
terapevticheskoi effektivnosti preparata Zeel T pri vnutrisustavnykh 
in”ektsiiakh i v vide mazi pri ionoforeze u bol’nykh s degenerativnymi 
izmeneniiami kolennykh sustavov [Comparative evaluation of the 
therapeutic efficiency of the medication Zeel T in case of intraarticu-
lar injections and in the form of ointment at ionophoresis in patients 
with degenerative changes of knee joints]. Biologicheskaia Meditsina. 
2000;(1):19-21. Russian.  
9. Khayne Kh. Zapusk immunologicheskikh vspo-mogatel’nykh reaktsiy, 
pri provedenii antigomotoksicheskoi terapii vospalenii sustavov [The 
launch of immunological auxiliary reactions, at the execution of antiho-
motoxic therapy of the inflammation of joints]. Biologicheskaia Terapiia. 
1998;(4):12-14. Russian.  
10. Bonfiglio Dzh, Tserea P, Konfalonieri N, Rossi Mauro, Setti Massimo. 
Issledovanie terapevticheskoi effektivnosti i perenosimosti antigomo-
toksicheskogo preparata Zeel T [Investigation of therapeutic efficiency 
and tolerability of the antihomotoxic medication Zeel T]. Biologicheskaia 
Terapiia. 2000;(1):13-18. Russian.  
11. Iatskevich IaE, Iatskevich AIa, Telishevskii IuG, Stasiuk MIu; Ministry of 
Health of Ukraine. Patogeneticheski napravlennaia medikamentoznaia 
terapiia destruktivno-distroficheskikh zabolevanii pozvonochnika 
i sustavov: Metodicheskie rekomendatsii [Pathogenetically directed 
medicinal therapy of destructive-dystrophic diseases of the vertebral 
column and joints: Methodological recommendation]. Kiev; 2005. 25 
p. Russian.  
12. Shtresser V, Vayzer Mikhael’. Gomeopaticheskoe lechenie gonartroza: 
rezul’taty dvoinogo slepogo issledovaniia [Homeopathic treatment of 
gonarthrosis: results of a double-blind study]. Biologicheskaia Meditsina. 
2001;(2):21-26. Russian.   
13. Potrafki B. Okolosustavnye in”ektsii preparata Zeel T pri gonartroze 
kak al’ternativa vnutrisustavnym in”ektsiiam [Periarticular injections of 
the medication Zeel T at gonarthrosis as an alternative to intraarticular 
injections]. Biologicheskaia Meditsina. 1996;(2):15-16. Russian.   
14. Telishevskii IuG, Telishevskaia MIu, Bilavka IO, Aleinik VA. Osteoar-
troz kolennykh sustavov u bol’nykh s somaticheskoi patologiei: opyt 
kompleksnogo konservativnogo lecheniia s vkliucheniem antigomo-
toksicheskikh preparatov [Osteoarthrosis of knee joints in patients with 
somatic pathology: the experience of complex conservative treatment 
with the inclusion of antihomotoxic medications]. Biologicheskaia 
Terapiia. 2009;(3):34-38. Russian. 
15. Zeel T: Monografiia o produkte [Monograph about the product Zeel T]. 
2nd ed. Baden-Baden: Biologishe Heilmittel Heel GmbKH, Germany; 
2015. 54 p. Russian.
16. Sukhovii MV, Aver’yanov EV, Semeniaka VI, Anoshina MIu, Shorop 
EV, Gavriliuk EI. Sravnitel’naia kharakteristika lokal’nogo primeneniia 
kortikosteroidov i antigomotoksicheskikh preparatov Tsel’ T i Traumel’ S 
v lechenii ostrykh gemartrozov kolennykh sustavov u bol’nykh gemofiliei 
[Comparative characteristics of the local use of corticosteroids and anti-
homotoxic medications Zeel T and Traumeel S in the treatment of acute 
hemarthrosis of knee joints in patients with hemophilia]. Biologicheskaia 
Terapiia. 2001;(3):23-29. Russian.
17. Rigan MM. Vliianie gliukokortikoidov i antigomotoksicheskikh pre-
paratov na sustavnoi khriashch pri ego mekhanicheskom povrezhdenii 
u sportsmenov: Avtoreferat dissertatsii na poluchenie nauchnoi stepeni 
kandidata meditsinskikh nauk [Influence of glucocorticoids and anti-
homotoxic medications on articular cartilage at its mechanical damage 
in athletes: Summary of Phd dissertation]. Kiev: Institut travmatologii 
i ortopedii AMN Ukrainy; 2006. 30 p. Russian. 
18. Mayko OIu. Effektivnost’ primeneniia metodov gomeopaticheskoi i 
biorezonansnoi terapii gonartroza v usloviiakh polikliniki: Avtoreferat 
dissertatsii na soiskanie uchenoi stepeni kandidata meditsinskikh nauk 
[Effectiveness of the methods of homeopathic and bioresonance therapy 
of gonarthrosis in the conditions of polyclinic: Summary of Phd dis-
sertation]. Orenburg: Orenburgskaia gosudarstvennaia meditsinskaia 
akademiia; 2000. Russian. 
19. Mayko OIu. Lechenie gonartroza gomeopaticheskim preparatom Zeel 
T v usloviiakh polikliniki [Treatment of gonarthrosis with the help of 
homeopathic medication Zeel T in the conditions of polyclinic]. Bio-
logicheskaia Meditsina.  2002;(2):19-26. Russian.
20. Naler G, Metel’mann Khorst V, Shperber Kh. Sravnitel’noe issledovanie 
effektivnosti terapii osteoartrita kolennogo sustava preparatom Zeel T i 
gialuronovoi kislotoi – rezul’taty randomizirovannogo, kontroliruemogo 
klinicheskogo issledovaniia [Comparative study of the effectiveness of 
the therapy of the osteoarthritis of knee joint with the help of medication 
Zeel T and hyaluronic acid - the results of randomized, controlled clinical 
investigation]. Biologicheskaia Meditsina. 2014;(1):43-50. Russian. 
21. Bachinger A, Rappenhoner B, Rychlik R. Social economic efficacy of 
Zeel-compositum in comparison with the acidum gyaluronicum in the 
patients with of osteoarthritis of the knee. Z Orthop. 1996;134(4):20-1.
22. Plotkin M, Smit Alta. Biomoduliatsia pri osteoartroze [Biomodulation 
in osteoarthrosis]. Biologicheskaia Meditsina. 2009;(2):11-13. Russian.
